APA (7th ed.) Citation

Monk, B. J., Coleman, R. L., Fujiwara, K., Wilson, M. K., Oza, A. M., Oaknin, A., . . . Kristeleit, R. S. (2021). ATHENA (GOG-3020/ENGOT-ov45): A randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer. International journal of gynecological cancer, 31(12), 1589-1594. https://doi.org/10.1136/ijgc-2021-002933

Chicago Style (17th ed.) Citation

Monk, Bradley J., et al. "ATHENA (GOG-3020/ENGOT-ov45): A Randomized, Phase III Trial to Evaluate Rucaparib as Monotherapy (ATHENA–MONO) and Rucaparib in Combination with Nivolumab (ATHENA–COMBO) as Maintenance Treatment Following Frontline Platinum-based Chemotherapy in Ovarian Cancer." International Journal of Gynecological Cancer 31, no. 12 (2021): 1589-1594. https://doi.org/10.1136/ijgc-2021-002933.

MLA (9th ed.) Citation

Monk, Bradley J., et al. "ATHENA (GOG-3020/ENGOT-ov45): A Randomized, Phase III Trial to Evaluate Rucaparib as Monotherapy (ATHENA–MONO) and Rucaparib in Combination with Nivolumab (ATHENA–COMBO) as Maintenance Treatment Following Frontline Platinum-based Chemotherapy in Ovarian Cancer." International Journal of Gynecological Cancer, vol. 31, no. 12, 2021, pp. 1589-1594, https://doi.org/10.1136/ijgc-2021-002933.